BRUSSELS, Belgium, March 4 /PRNewswire/ -- Unibioscreen S.A., the Brussels specialist oncology company, is pleased to announce that it has succeeded in the closing of a new financing round of EUR 5 million from existing shareholders (ING, Société Générale Asset Management, E-capital, Brustart, UFG-Group and business angels) and from Hunza Ventures. This round brings the total amount raised since the Company's inception to date to EUR 27 million.
It strengthens the company's balance sheet and allows the progression of Unibioscreen's two lead compounds, UNBS1450 and UNBS5162, into clinical trials in cancer patients by mid 2008. These two compounds present novel mode of action and will be developed respectively in Europe and in the US.